LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY

被引:1
作者
Johnston, D.
Banerji, A.
Riedl, M.
Zuraw, B.
Lumry, W.
Bernstein, J.
Li, H.
Lu, P.
Hao, J.
Gower, R.
机构
关键词
D O I
10.1016/j.anai.2018.09.114
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
P166
引用
收藏
页码:S36 / S36
页数:1
相关论文
共 50 条
[31]   4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults [J].
Nolan, Terry ;
Bhusal, Chiranjiwi ;
Beran, Jiri ;
Bloch, Mark ;
Cetin, Benhur S. ;
Dinleyici, Ener C. ;
Drazan, Daniel ;
Kokko, Satu ;
Koski, Susanna ;
Laajalahti, Outi ;
Langley, Joanne M. ;
Ramet, Mika ;
Richmond, Peter C. ;
Silas, Peter ;
Tapiero, Bruce ;
Tiong, Florence ;
Tipton, Mary ;
Ukkonen, Benita ;
Ulukol, Betul ;
Lattanzi, Maria ;
Trapani, Mauro ;
Willemsen, Arnold ;
Toneatto, Daniela .
OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (11)
[32]   Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies [J].
Mullins, Garrett R. ;
Hodsdon, Michael E. ;
Li, Ying Grace ;
Anglin, Greg ;
Urva, Shweta ;
Schneck, Karen ;
Bardos, Jennifer N. ;
Martins, Ricardo Fonseca ;
Brown, Katelyn ;
Calderon, Boris .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02) :361-369
[33]   Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study [J].
Gutzmer, R. ;
Rivoltini, L. ;
Levchenko, E. ;
Testori, A. ;
Utikal, J. ;
Ascierto, P. A. ;
Demidov, L. ;
Grob, J. J. ;
Ridolfi, R. ;
Schadendorf, D. ;
Queirolo, P. ;
Santoro, A. ;
Loquai, C. ;
Dreno, B. ;
Hauschild, A. ;
Schultz, E. ;
Lesimple, T. P. ;
Vanhoutte, N. ;
Salaun, B. ;
Gillet, M. ;
Jarnjak, S. ;
Alves, P. M. De Sousa ;
Louahed, J. ;
Brichard, V. G. ;
Lehmann, F. F. .
ESMO OPEN, 2016, 1 (04)
[34]   Efficacy of lanadelumab in patients with HAE is independent of body mass index: Findings from the HELP study [J].
Zanichelli, A. ;
Hebert, J. ;
Soteres, D. ;
Hao, J. ;
Lu, P. ;
Busse, P. .
ALLERGY, 2018, 73 :722-723
[35]   Consistent Reduction in HAE Attack Rate with Lanadelumab Regardless Of Baseline Attack Frequency: Interim Findings From the Phase 3 HELP Study Open Label Extension (OLE) [J].
Banerji, Aleena ;
Riedl, Marc ;
Tachdjian, Raffi ;
Nurse, Christina ;
Paes, Kim ;
Li, Huamin ;
Kiani-Alikhan, Sorena .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) :AB103-AB103
[36]   Safety, tolerability and immunogenicity of natalizumab: Results from the AFFIRM trial [J].
O'Connor, P ;
Havrdova, E ;
Hutchinson, M ;
Kappos, L ;
Phillips, JT ;
Polman, C ;
Lublin, F ;
Giovannoni, G ;
Wajgt, A ;
Lynn, F ;
Tool, M ;
Panzara, M ;
Sandrock, A .
NEUROLOGY, 2005, 64 (06) :A146-A146
[37]   Biosimilar candidate ABP 501: immunogenicity results from 2 phase 3 studies [J].
Kaur, P. ;
Krishnan, E. ;
Zhang, N. ;
Kaliyaperumal, A. .
JOURNAL OF CROHNS & COLITIS, 2016, 10 :S361-S361
[38]   Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials [J].
Beran, Jiri ;
Lickliter, Jason D. ;
Schwarz, Tino F. ;
Johnson, Casey ;
Chu, Laurence ;
Domachowske, Joseph B. ;
Van Damme, Pierre ;
Withanage, Kanchanamala ;
Fissette, Laurence A. ;
David, Marie-Pierre ;
Maleux, Koen ;
Schmidt, Alexander C. ;
Picciolato, Marta ;
Dieussaert, Ilse .
JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (10) :1616-1625
[39]   Efficacy and Safety of Lanadelumab in pediatric Patients with hereditary Angioedema aged 2 to < 12 Years: Results of the open-label, multi-centric Phase 3 SPRING Study [J].
Kappek, M. ;
Maurer, M. ;
Lumry, W. R. ;
Li, H. H. ;
Aygoeren-Pursun, E. ;
Busse, P. ;
Jacobs, J. ;
Nurse, C. .
ALLERGOLOGIE, 2023, 46 (08) :560-560
[40]   Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies [J].
Craig, Timothy ;
Zaragoza-Urdaz, Rafael ;
Anderson, John ;
Li, Huamin ;
Paes, Kim ;
Ren, Hong ;
Juethner, Salome .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) :AB21-AB21